Quarterly Activities/Appendix 4C Cash Flow Report

• USD$1.3M (~AUD$2.0M) contract signed with Provider Network Solutions (PNS) for a commercial pilot project
• Completed AUD$8.0M capital raise led by the Wallabi Group
• Expanded US opportunities validated through market study and stakeholder meetings

The June 2025 quarter marked a period of strong operational execution and commercial momentum for Singular Health Group Limited (ASX: SHG). Key highlights include: signing a USD$1.3M (~AUD$2.0M) contract with Provider Network Solutions (PNS) for a commercial pilot project; completing an AUD$8.0M capital raise led by the Wallabi Group; expanding US opportunities validated through site visits, stakeholder meetings, and a Signify Research market study; submitting various commercial proposals to major US institutions; achieving ISO 13485 re-certification, SOC 2 Type 2 and HIPAA compliance; appointing a US radiology consultant; progressing pilot opportunities in the Australian market; and enhancing product development. The Company is well-positioned to execute its US market entry strategy and unlock significant commercial value through the PNS pilot and associated partnerships, while also continuing engagement in the Australian market and further investment in product development to support long-term global expansion.

The Company is targeting a total addressable market exceeding USD$19 billion in the US, with approximately 1.3 million primary care physicians representing an average licence opportunity of USD$800 per year.

Building on the momentum of the June quarter, Singular Health is focused on delivering tangible outcomes from its pilot programs, advancing discussions with prospective clients, and accelerating its pathway to national deployment in the United States. In parallel, the Company will continue engagement in the Australian market and further investment in product development to support long-term global expansion and value creation.